Veerhealth Care Proposes ₹20.25 Crore Warrant Issue for Expansion

Veerhealth Care Ltd. is proposing to raise up to ₹20.25 crore by issuing 1 crore fully convertible warrants at ₹20.25 per warrant. This capital infusion is intended to expand its manufacturing capacity, particularly for plant and machinery, and for general corporate purposes. Shareholders will vote on the preferential issue via postal ballot e-voting from April 1 to April 30, 2026.

The Proposed Warrant Issue

The company has issued a notice detailing its plan to raise ₹20.25 crore through the issuance of up to 1 crore fully convertible warrants at ₹20.25 each.

Funding Expansion and Operations

The capital raised is primarily designated for expanding manufacturing capacity, with significant allocations for plant and machinery. A portion of the funds, specifically ₹5.05 crore, is earmarked for general corporate purposes.

Shareholder Vote and Timeline

Shareholders will decide the fate of this preferential issue. They can cast their vote either for or against the plan through e-voting, which is open from April 1 to April 30, 2026.

Potential Impact on Shareholders

If the warrants are approved and subsequently converted into shares, the total number of outstanding shares will increase. This conversion could potentially dilute the ownership stake of existing shareholders.

Identified Risks

The company has noted potential risks, including delays in allotment completion if regulatory approvals are not secured promptly. Additionally, the specific amounts allocated for the expansion and corporate purposes might vary by up to 10% due to unforeseen circumstances.

Key Financials

For fiscal year 2025, Veerhealth Care reported consolidated revenue of ₹50 crore and consolidated profit after tax of ₹2 crore.

What Investors Should Watch

Investors will be tracking the outcome of the shareholder e-voting, which concludes on April 30, 2026. Post-approval, attention will turn to the formal allotment of warrants, the company's progress in utilizing the funds for plant machinery and other stated objectives, and any future announcements regarding the conversion of warrants into equity shares. Management commentary on expansion timelines and projected revenue impact will also be important.